Preclinical Pharmacokinetics and Pharmacodynamic Target of SCY-078, a First-in-Class Orally Active Antifungal Glucan Synthesis Inhibitor, in Murine Models of Disseminated Candidiasis.

S. Wring, R. Randolph, S. Park, G. Abruzzo, Q. Chen, A. Flattery, G. Garrett, M. Peel, R. Outcalt, K. Powell, M. Trucksis, D. Angulo, K. Borroto-Esoda
Antimicrobial Agents and Chemotherapy
March 2017

The Emerging Candida auris: Characterization of Growth Phenotype, Virulence Factors, Antifungal Activity, and Effect of SCY-078, a Novel Glucan Synthesis Inhibitor, on Growth Morphology and Biofilm Formation.

E. Larkin, C. Hager, J. Chandra, P. Mukherjee, M. Retuerto, I. Salem, L. Long, N. Isham, L. Kovanda, K. Borroto-Esoda, S. Wring, D. Angulo, M. Ghannoum
Antimicrobial Agents and Chemotherapy
February 2017

SCY-078 Is Fungicidal against Candida Species in Time-Kill Studies.

B. Scorneaux, D. Angulo, K. Borroto-Esoda, M. Ghannoum, M. Peel, S. Wring
Antimicrobial Agents and Chemotherapy
February 2017

• « Previous
• 1
• 2